Dexmedetomidine and Iatrogenic Withdrawal Syndrome in Critically Ill Children

Barbara M Geven1, Jolanda M Maaskant2, Catherine S Ward3

  • 1Barbara M. Geven is a pediatric intensive care nurse and clinical epidemiologist, Amsterdam UMC/Emma Children's Hospital, University of Amsterdam, Amsterdam, the Netherlands.

Critical Care Nurse
|February 9, 2021
PubMed

Insights

Supplemental dexmedetomidine did not prevent iatrogenic withdrawal syndrome in pediatric intensive care unit patients on mechanical ventilation. Higher midazolam doses were linked to increased withdrawal symptoms.

Area of Science:

  • Pediatric Intensive Care
  • Pharmacology
  • Critical Care Medicine

Background:

  • Iatrogenic withdrawal syndrome (IWS) is a common adverse effect in pediatric patients on mechanical ventilation, with incidence up to 64.6%.
  • Standard sedatives and analgesics may be insufficient, leading to the use of supplemental dexmedetomidine.
  • The impact of dexmedetomidine on IWS in this population remains unclear.

Purpose of the Study:

  • To investigate the potential preventive effect of dexmedetomidine on IWS.
  • To assess dexmedetomidine as an adjunct to standard morphine and midazolam regimens.
  • To evaluate IWS development in mechanically ventilated pediatric intensive care unit patients.

Main Methods:

  • Retrospective observational study in a 10-bed general pediatric intensive care unit.
  • Data collected from 102 patients receiving mechanical ventilation.
  • Iatrogenic withdrawal syndrome assessed using the Sophia Observation withdrawal Symptoms-scale.

Main Results:

  • Cumulative dexmedetomidine dose showed no preventive effect on IWS (P = .19).
  • After adjusting for baseline characteristics, cumulative midazolam dose was a significant risk factor for IWS (P < .03).

Conclusions:

  • Supplemental dexmedetomidine does not appear to prevent IWS in pediatric ICU patients.
  • Midazolam cumulative dose is identified as a significant risk factor for developing IWS.
  • Further research may be needed to identify effective strategies for preventing IWS.
Abstract

Related Concept Videos

Parenteral Anesthetics: Overview01:24

Parenteral Anesthetics: Overview

Intravenous anesthetics are drugs administered parenterally to induce anesthesia or sedation. Propofol is a widely used agent formulated as a 1% emulsion in soybean oil, glycerol, and egg phosphatide. It induces rapid anesthesia primarily due to its rapid distribution from the bloodstream to target tissues and is metabolized in the liver. However, it can cause significant pain on injection and hypertriglyceridemia. Fospropofol, a water-based prodrug of propofol, lacks these adverse effects.
418
Sedatives and Hypnotics Drugs: Miscellaneous Agents01:17

Sedatives and Hypnotics Drugs: Miscellaneous Agents

Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
328
Skeletal Muscle Relaxants: Adverse Effects01:21

Skeletal Muscle Relaxants: Adverse Effects

Skeletal muscle relaxants are widely used for muscle paralysis and relieving pain following any muscle injury or stiffness. However, depending on the drug type, they can have adverse effects that range from mild to severe. Usually, nondepolarizing neuromuscular blockers have minimal side effects. For example, drugs like d-tubocurarine, cisatracurium, and rocuronium cause hypotension, whereas drugs like baclofen, when stopped abruptly, can lead to the recurrence of spastic conditions.
Unlike...
621
Depolarizing Blockers: Pharmocokinetics01:19

Depolarizing Blockers: Pharmocokinetics

Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
469
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
105
Stages of General Anesthesia01:22

Stages of General Anesthesia

Various sedation levels offer significant advantages in facilitating procedural interventions for patients undergoing medical or invasive surgical procedures. These levels span from anxiolysis to general anesthesia, providing a spectrum of sedative effects to cater to specific patient needs. Anxiolysis reduces anxiety and is achieved through minimal sedation, enabling patients to remain awake and responsive while feeling more at ease during the procedure. This level can benefit minor...
1.1K